Variable | Total population | Breakdown by BMI (kg/m2) | |||||
---|---|---|---|---|---|---|---|
<18.5 | 18.5-24.9 | 25-29.9 | 30-39.9 | ≥40 | p-value* | ||
(n = 903) | (n = 15; 1.8 %) | (n = 174; 20.7 %) | (n = 293; 34.8 %) | (n = 288; 34.2 %) | (n = 72; 8.6 %) | ||
Male gender | 515 (57Â %) | 2 (13.3Â %) | 96 (55.2Â %) | 181 (61.8Â %) | 169 (58.7Â %) | 35 (48.6Â %) | 0.002 |
Age (years) | 66.26 ± 13.62 | 56.5 ± 18.8 | 67 ± 15.7 | 68.3 ± 13 | 65.4 ± 12.3 | 61.0 ± 11.1 | <0.001 |
Race | Â | Â | Â | Â | Â | Â | 0.036 |
 Caucasian | 708 (78.4 %) | 11 (73.3 %) | 137 (78.7 %) | 241 (82.3 %) | 226 (78.5 %) | 51 (70.8 %) |  |
 Non-Caucasian | 115 (12.7 %) | 2 (13.3 %) | 29 (16.6 %) | 24 (8.2 %) | 36 (12.5 %) | 14 (19.4 %) |  |
 Not stated | 80 (8.9 %) | 2 (13.3 %) | 8 (4.6 %) | 28 (9.6 %) | 26 (9.0 %) | 7 (9.7 %) |  |
Cause of CKD | Â | Â | Â | Â | Â | Â | <0.001 |
 Diabetic nephropathy | 243 (26.9 %) | 0 (0.0 %) | 32 (18.4 %) | 59 (20.1 %) | 98 (34.0 %) | 33 (45.8 %) |  |
 Glomerulonephritis | 75 (8.3 %) | 2 (13.3 %) | 17 (9.8 %) | 23 (7.8 %) | 20 (6.9 %) | 5 (6.9 %) |  |
 Cystic kidney disease | 26 (2.9 %) | 1 (6.7 %) | 7 (4.0 %) | 13 (4.4 %) | 4 (1.4 %) | 1 (1.4 %) |  |
 Other | 559 (61.9 %) | 12 (80.0 %) | 118 (67.8 %) | 198 (67.6 %) | 166 (57.6 %) | 33 (45.8 %) |  |
Comorbidities | Â | Â | Â | Â | Â | Â | Â |
 Diabetes mellitus (n = 902) | 387 (42.9 %) | 0 (0.0 %) | 49 (28.2 %) | 114 (28.9 %) | 146 (50.7 %) | 47 (66.2 %) | <0.001 |
 CAD (n = 823) | 270 (32.8 %) | 1 (7.1 %) | 49 (31.0 %) | 93 (33.6 %) | 83 (32.5 %) | 21 (33.9 %) | 0.351 |
 CLD (n = 872) | 117 (13.4 %) | 1 (6.7 %) | 21 (12.4 %) | 38 (13.5 %) | 36 (13.1 %) | 16 (22.5 %) | 0.228 |
 CBVD (n = 870) | 110 (12.6 %) | 0 (0.0 %) | 17 (10.2 %) | 39 (13.9 %) | 40 (14.2 %) | 8 (11.6 %) | 0.393 |
 PVD (n = 854) | 140 (16.4 %) | 0 (0.0 %) | 20 (12.2 %) | 46 (16.5 %) | 54 (19.8 %) | 12 (17.9 %) | 0.115 |
Medication use | Â | Â | Â | Â | Â | Â | Â |
 Lipid lowering (n = 839) | 402 (47.9 %) | 0 (0.0 %) | 72 (43.4 %) | 127 (46.4 %) | 143 (54.2 %) | 38 (56.7 %) | <0.001 |
 ACEi/ARB (n = 839) | 509 (60.7 %) | 6 (40.0 %) | 93 (56.0 %) | 166 (60.6 %) | 168 (63.6) | 50 (74.6 %) | 0.032 |
 Antihypertensive (n = 822) | 655 (79.7 %) | 8 (53.3 %) | 125 (75.8 %) | 220 (80.9 %) | 217 (82.2 %) | 56 (84.4 %) | 0.033 |
 EPO (n = 839) | 29 (3.5 %) | 1 (6.7 %) | 8 (4.8 %) | 10 (3.6 %) | 8 (3.0 %) | 2 (3.0 %) | 0.863 |
eGFR (n = 903) | 37.9 ± 11.7 | 38.3 ± 12.2 | 38.3 ± 12.4 | 37.4 ± 11.3 | 37.9 ± 11.2 | 39.9 ± 12.0 | 0.573 |
 Stage 3 | 654 (72.4 %) | 11 (1.8 %) | 124 (20.2 %) | 210 (34.3 %) | 212 (34.6 %) | 56 (9.1 %) |  |
 Stage 4 | 249 (27.6 %) | 4 (1.7 %) | 50 (21.8 %) | 83 (36.2 %) | 76 (33.2 %) | 16 (7.0 %) |  |
Proteinuria (n = 780) |  |  |  |  |  |  | 0.493 |
 Microproteinuria | 459 (58.8 %) | 6 (54.5 %) | 88 (59.5 %) | 163 (64.2 %) | 138 (54.3 %) | 40 (59.7 %) |  |
 Macroproteinuria | 293 (37.6 %) | 5 (45.5 %) | 56 (37.8 %) | 83 (32.7 %) | 104 (40.9 %) | 23 (34.3 %) |  |
Obesity measures | Â | Â | Â | Â | Â | Â | Â |
 WC (n = 594) | 101.6 ± 16.1 | 69.4 ± 6.9 | 86.1 ± 8.2 | 98.5 ± 8.2 | 111.2 ± 10.3 | 130.6 ± 12.6 | <0.001 |
 ConI (n = 588) | 1.33 ± 0.10 | 1.21 ± 0.11 | 1.28 ± 0.09 | 1.33 ± 0.09 | 1.36 ± 0.09 | 1.39 ± 0.09 | <0.001 |